🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Ying Huang

Fujian Medical University

ORCID: 0000-0001-9910-1212

Also affiliated with Army Medical University, Guilin Medical University, Chengdu Medical College, The Ohio State University Wexner Medical Center, The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine, Xinqiao Hospital, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Chengdu Second People's Hospital, Union Hospital, Union Hospital, Second Affiliated Hospital of Chengdu University of Traditional Chinese, Chongqing Medical University

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 12 papers. Top paper: “Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia”.

Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia

Journal of Clinical Oncology(2020)10.1200/jco.20.00491
N/A
3.8DataRank · unranked
105 citations

Ying Huang, Amy S. Ruppert, Lynne V. Abruzzo, Barbara L. Andersen, Farrukh T. Awan +14 more

Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3867
N/A
1.0DataRank · unranked
26 citations

Ying Huang, Amy S. Ruppert, Janek S. Walker, Daniel Canfield, Casey B. Cempre +13 more

Feasibility of implementing an exercise intervention in older adults with hematologic malignancy

Journal of Geriatric Oncology(2021)10.1016/j.jgo.2021.07.010
N/A
0.543DataRank · unranked
9 citations

Ying Huang, Desirée Jones, Carolyn J. Presley, Jordon Jaggers, ReNea Owens +3 more

Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL

Blood Cancer Journal(2025)10.1038/s41408-025-01236-6
N/A
0.396DataRank · unranked
13 citations

Ying Huang, Sarah Miller, John N. Allan, Seema A. Bhat, David A. Bond +40 more

Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-center retrospective study

Therapeutic Advances in Hematology(2022)10.1177/20406207221112900
N/A
0.345DataRank · unranked
9 citations

Ying Huang, Emily Dotson, David A. Bond, John Reneau, Narendranath Epperla +7 more

A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years

Cancer Research Communications(2025)10.1158/2767-9764.crc-25-0091
N/A
0.216DataRank · unranked
3 citations

Ronan Swords, Ying Huang, Shelley Orwick, Daelynn R. Buelow, Nicole Abbott +23 more

Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists

Blood Advances(2020)10.1182/bloodadvances.2020002593
N/A
0DataRank · unranked
23 citations

Ying Huang, Emily Dotson, Shane Sheredy, Seema A. Bhat, John C. Byrd +11 more

Integration of a Geriatric Assessment With Intervention in the Care of Older Adults With Hematologic Malignancies

Frontiers in Oncology(2021)10.3389/fonc.2021.775050
N/A
0DataRank · unranked
15 citations

Ying Huang, Ashleigh Keiter, Allesia Funderburg, Colin Kloock, Nicholas Yuhasz +9 more

Data from Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study

(2023)10.1158/1078-0432.c.6532472
N/A
0DataRank · unranked
0 citations

Ying Huang, Amy S. Ruppert, Janek S. Walker, Daniel Canfield, Casey B. Cempre +13 more

Microbial riboflavin inhibits ceramide synthase 3 to lower ceramide (d18:1/26:0) and delay colorectal cancer progression

Cell Metabolism(2025)10.1016/j.cmet.2025.06.002
N/A
0DataRank · unranked
19 citations

Yi Zhang, Bora Kim, Guangyi Zeng, Pengcheng Wang, Weike Shaoyong +23 more

Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients

Frontiers in Oncology(2021)10.3389/fonc.2020.575168
N/A
0DataRank · unranked
17 citations

Ying Huang, Nita Williams, Naresh Bumma, Abdullah Khan, Maria Chaudhry +5 more

CEACAM6 as a candidate biomarker for pelareorep sensitivity in pancreatic adenocarcinoma (PDAC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.4_suppl.746
N/A
0DataRank · unranked
0 citations

Jacob S. Yount, Jason J. David, Mindy Hoang, Colin W. Stets, Tanios Bekaii‐Saab +6 more